Immunome is a biotechnology company developing oncology therapeutics with a focus on antibody-drug conjugates (ADCs) and related targeted cancer treatments. The company advances a portfolio including an oral gamma secretase inhibitor for desmoid tumors, ROR1-targeted and FAP-targeted therapies, and solid tumor ADCs, leveraging proprietary payload technology designed to overcome resistance mechanisms and enhance efficacy. Immunome generates no current revenue but holds global commercial rights to its lead assets and plans focused commercialization strategies in the United States while pursuing partnerships internationally, with revenue dependent on regulatory approvals, market adoption, and reimbursement coverage.